Insider-Transaktionen

EDGAR

Neurogene Inc.

Von Direktoren, Führungskräften und 10-%-Eignern auf den SEC-Formularen 3, 4 und 5 gemeldete Transaktionen, aus dem XML jeder Einreichung gelesen. Codes und ihr Wortlaut stammen von der SEC.

Das Formular 4 ist innerhalb von zwei Geschäftstagen nach der Transaktion einzureichen; die jüngsten Geschäfte sind daher möglicherweise noch nicht gemeldet.

Zeitfenster: Transaktionen ab dem 17. Nov. 2025.

Käufe am offenen Markt (Code P)
0 Transaktionen, — Aktien
Verkäufe am offenen Markt (Code S)
17 Transaktionen, 41.580 Aktien
Summe Aktien × Preis je Aktie: 1.133.591,8388

Die Summen addieren die aufgeführten eingereichten Transaktionen; sie zählen das Gemeldete und messen keine Richtung.

1–32 von 32 angezeigt

Insider-Transaktionen, neueste zuerst, wie auf den SEC-Formularen 3, 4 und 5 eingereicht
DatumMeldende PersonCodeErworben oder veräußertAktienPreis je Aktie, wie eingereichtWert (abgeleitet)Aktien danach im BesitzDirekt oder indirektKästchen zu Rule 10b5-1AnmerkungenQuelle
22. Sept. 2026 Eingereicht am 2. Okt. 2026McMinn Rachel Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Erworben (A)75625,32
19.141,92

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 19141.92.

1.345.063Direkt (D) Nein
F1
  • F1 Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.
Einreichung öffnen 0001606302-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
22. Sept. 2026 Eingereicht am 2. Okt. 2026McMinn Rachel Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (756) — Ausübungspreis 25.32
Veräußert (D)7560—0Direkt (D) Nein
F2
  • F2 This option is fully vested and exercisable.
Einreichung öffnen 0001606302-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
7. Juli 2026 Eingereicht am 7. Juli 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.20036,134
151.762,8

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 151762.800.

84.040Direkt (D) Ja
F1, F4, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.455, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.
Einreichung öffnen 0001543663-26-000017 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Juli 2026 Eingereicht am 7. Juli 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)60036,021
21.612,6

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 21612.600.

88.240Direkt (D) Ja
F1, F2, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.00 to $36.035, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Following completion of all sales reported on this Form 4, the reporting person no longer holds any shares jointly with her spouse.
Einreichung öffnen 0001543663-26-000017 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Juli 2026 Eingereicht am 2. Juli 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.53134,579
87.519,449

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 87519.449.

90.370Direkt (D) Ja
F1, F4, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000015 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
2. Juli 2026 Eingereicht am 2. Juli 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)1.53035,227
53.897,31

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 53897.310.

88.840Direkt (D) Ja
F1, F5, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000015 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
1. Juli 2026 Eingereicht am 2. Juli 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)73934,059
25.169,601

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 25169.601.

92.901Direkt (D) Ja
F1, F2, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000015 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Mai 2026 Eingereicht am 8. Mai 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.80030,0732
144.351,36

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 144351.3600.

98.440Direkt (D) Ja
F1, F2, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.31, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000013 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
6. Mai 2026 Eingereicht am 8. Mai 2026Cvijic Christine Mikail Director · Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.80032,4358
155.691,84

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 155691.8400.

93.640Direkt (D) Ja
F1, F4, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.02 to $32.695, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 9,600 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000013 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
5. Mai 2026 Eingereicht am 7. Mai 2026Shafer Christina Officer: Chief Commercial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Non-Qualified Stock Option (right to buy) — Basiswert Common Stock (120.000) — Ausübungspreis 28.94
Erworben (A)120.0000—120.000Direkt (D) Nein
F1
  • F1 This option represents the right to purchase 120,000 shares of the Issuer's common stock, one quarter of which will vest on April 20, 2027 with the remaining three quarters vesting on the 20th of each month in equal monthly installments through April 20, 2030, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001934412-26-000006 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
26. März 2026 Eingereicht am 30. März 2026Cvijic Christine Mikail Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.55821,6247
55.315,9826

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 55315.9826.

103.240Direkt (D) Ja
F1, F2, F3
  • F1 On March 26, 2026, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.10 to $21.91, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000011 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
26. März 2026 Eingereicht am 30. März 2026Jordan Julie Officer: Chief Medical Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)82821,8932
18.127,5696

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 18127.5696.

12.472Direkt (D) Ja
F1, F2, F3
  • F1 On March 26, 2026, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.68 to $22.19, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Consist of (a) 5,600 restricted stock units, which vest annually in equal installments on March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units which vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Einreichung öffnen 0001968554-26-000005 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
26. März 2026 Eingereicht am 30. März 2026McMinn Rachel Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)3.35222,0749
73.995,0648

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 73995.0648.

1.344.307Direkt (D) Ja
F1, F2, F3
  • F1 On March 26, 2026, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.67to $22.50, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 15,933 restricted stock units that vest annually in equal installments on March 23, 2027 and March 23, 2028; and (b) 25,900 restricted stock units that vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029.
Einreichung öffnen 0001606302-26-000005 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 17. März 2026Cobb Stuart Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)3.99120,41
81.456,31

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 81456.31.

33.303Direkt (D) Ja
F1, F2, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.94 to $20.93, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Einreichung öffnen 0001994301-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 17. März 2026Cobb Stuart Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.65821,34
56.721,72

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 56721.72.

30.645Direkt (D) Ja
F1, F4, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.97 to $21.96, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Einreichung öffnen 0001994301-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 17. März 2026Cobb Stuart Officer: Chief Scientific Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)14822,08
3.267,84

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 3267.84.

30.497Direkt (D) Ja
F1, F5, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 6, 2025.
  • F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.97 to $22.16, inclsuive. The reporting person undertakes to provide Neurogene Inc. the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 6,797 restricted stock units granted on March 13, 2025, which will vest on March 13, 2027; (b) 7,200 restricted stock units granted on March 23, 2025, which will vest annually in equal installments on March 23, 2026, March 23, 2027 and March 23, 2028 and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Einreichung öffnen 0001994301-26-000004 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 17. März 2026Cvijic Christine Mikail Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)2.38720,4224
48.748,2688

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 48748.2688.

107.456Direkt (D) Ja
F1, F2, F3
  • F1 On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.92 to $20.87, inclusive. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the SEC), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 17. März 2026Cvijic Christine Mikail Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)1.39521,2451
29.636,9145

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 29636.9145.

106.061Direkt (D) Ja
F1, F4, F3
  • F1 On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
  • F4 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
13. März 2026 Eingereicht am 17. März 2026Cvijic Christine Mikail Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)26322,0195
5.791,1285

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 5791.1285.

105.798Direkt (D) Ja
F1, F5, F3
  • F1 On March 12, 2025, a Restricted Stock Unit (RSU) held by the Reporting Person vested in part. The shares issuable on vesting of the RSU are reported as shares held by the Reporting Person. The award agreement for the RSU provides that the Registrant shall sell a number of shares necessary to cover the Reporting Person's tax withholding responsibility created by the vesting event, with no election made by the Reporting Person. The sales reported on this Form 4 relate exclusively to this mandatory sale upon vesting of the RSU.
  • F5 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.92 to $22.075, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000007 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
27. Feb. 2026 Eingereicht am 3. März 2026Cvijic Christine Mikail Officer: President and CFO
S

Open market or private sale of non-derivative or derivative security

Common Stock
Veräußert (D)4.80025,1096
120.526,08

Abgeleitet: Aktien × Preis je Aktie. Exakter Wert 120526.0800.

109.843Direkt (D) Ja
F1, F2, F3
  • F1 The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
  • F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.325. The reporting person undertakes to provide Neurogene Inc. (the Company), any securityholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  • F3 Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 19,200 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000005 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026McMinn Rachel Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Erworben (A)25.9000—1.347.659Direkt (D) Nein
F1, F2
  • F1 Consist of 25,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
  • F2 Includes (a) 23,900 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 25,900 restricted stock units granted on February 20, 2029, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Due to an administrative error, the amount reported in Column 5 on the Reporting Person's Form 4 filed on March 28, 2025 was understated by the 47,500 shares reported as purchased by the Reporting Person on the Reporting Person's Form 4 filed on November 25, 2024. This Form 4 reflects the correct amount of common stock beneficially owned by the Reporting Person.
Einreichung öffnen 0001606302-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026McMinn Rachel Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (155.100) — Ausübungspreis 17.64
Erworben (A)155.1000—155.100Direkt (D) Nein
F3
  • F3 This option represents the right to purchase 155,100 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001606302-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Freedland Cory S. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Non-Qualified Stock Option (right to buy) — Basiswert Common Stock (12.050) — Ausübungspreis 17.64
Erworben (A)12.0500—12.050Direkt (D) Nein
F1
  • F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001832569-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Noonberg Sarah B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Non-Qualified Stock Option (right to buy) — Basiswert Common Stock (12.050) — Ausübungspreis 17.64
Erworben (A)12.0500—12.050Direkt (D) Nein
F1
  • F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001706301-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Cobb Stuart Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Erworben (A)16.5000—37.294Direkt (D) Nein
F1, F2
  • F1 Consist of 16,500 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
  • F2 Consist of (a) 13,594 restricted stock units remaining from a grant of 20,391 restricted stock units granted on March 13, 2024, which vests annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 7,200 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 16,500 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Einreichung öffnen 0001994301-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Jordan Julie Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Erworben (A)4.9000—13.300Direkt (D) Nein
F1, F2
  • F1 Consist of 4,900 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
  • F2 Consist of (a) 8,400 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (b) 4,900 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029, in each case subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
Einreichung öffnen 0001968554-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Jordan Julie Officer: Chief Medical Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (29.600) — Ausübungspreis 17.64
Erworben (A)29.6000—29.600Direkt (D) Nein
F3
  • F3 This option represents the right to purchase 29,600 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001968554-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026PALEKAR ROHAN Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Non-Qualified Stock Option (right to buy) — Basiswert Common Stock (12.050) — Ausübungspreis 17.64
Erworben (A)12.0500—12.050Direkt (D) Nein
F1
  • F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001628280-26-011325 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026BAFFI ROBERT Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Non-Qualified Stock Option (right to buy) — Basiswert Common Stock (12.050) — Ausübungspreis 17.64
Erworben (A)12.0500—12.050Direkt (D) Nein
F1
  • F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001274826-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Cvijic Christine Mikail Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Erworben (A)22.0000—114.643Direkt (D) Nein
F1, F2
  • F1 Consist of 22,000 restricted stock units, which will vest in three equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued provision of services to the Issuer on each vesting date.
  • F2 Includes (a) 21,269 restricted stock units remaining from a grant of 31,900 restricted stock units granted on March 13, 2024 that vest annually in equal installments on March 13, 2025, March 13, 2026 and March 13, 2027; (b) 20,300 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2026, March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, 24,000 are held jointly by the reporting person and her spouse, David Cvijic.
Einreichung öffnen 0001543663-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Cvijic Christine Mikail Officer: President and CFO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Stock Option (Right to Buy) — Basiswert Common Stock (131.900) — Ausübungspreis 17.64
Erworben (A)131.9000—131.900Direkt (D) Nein
F3
  • F3 This option represents the right to purchase 131,900 shares of the Issuer's common stock, one quarter of which will vest on the first anniversary of the grant date with the remaining three quarters vesting in equal monthly installments through the fourth anniversary of the grant date, subject to the Reporting Person's continued provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001543663-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten
20. Feb. 2026 Eingereicht am 24. Feb. 2026Woods Keith Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivatives Wertpapier: Non-Qualified Stock Option (right to buy) — Basiswert Common Stock (12.050) — Ausübungspreis 17.64
Erworben (A)12.0500—12.050Direkt (D) Nein
F1
  • F1 The option vests as to 1/12 of the total shares monthly beginning March 20, 2026 until the option is fully vested on February 20, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Einreichung öffnen 0001996804-26-000002 Aus dem XML der Einreichung gelesen Diese Zeile anfechten

Institutionelle Halter (Formular 13F)

Quartal zum 2026-09-30: 8.793 Einreichungen gelesen, die jüngste vom 16. Nov. 2026. Vorquartal zum 2026-06-30: 9.164 Einreichungen gelesen.

1–50 von 139 angezeigt

Institutionelle Halter, größte Position zuerst, wie eingereicht
ManagerAktien oder NennbetragWert wie eingereichtDifferenz zum VorquartalQuelle
JENNISON ASSOCIATES LLC Teilweise unter einem anderen Manager gemeldet2.229.082 SH62.013.064 DollarHöher um 1.710.500 Vorquartal: 518.582Einreichung öffnen 0000053417-26-000068 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
SAMSARA BIOCAPITAL, LLC 1.867.127 SH51.943.473 DollarHöher um 150.000 Vorquartal: 1.717.127Einreichung öffnen 0001744967-26-000014 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Casdin Capital, LLC 1.585.361 SH44.104.743 DollarHöher um 40.000 Vorquartal: 1.545.361Einreichung öffnen 0000919574-26-008113 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Redmile Group, LLC 1.562.199 SH43.460.376 DollarHöher um 150.000 Vorquartal: 1.412.199Einreichung öffnen 0000905148-26-004923 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
RTW INVESTMENTS, LP 1.512.456 SH42.076.526 DollarHöher um 150.000 Vorquartal: 1.362.456Einreichung öffnen 0001493215-26-000214 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
BlackRock, Inc. Teilweise unter einem anderen Manager gemeldet1.471.936 SH40.949.259 DollarHöher um 413.953 Vorquartal: 1.057.983Einreichung öffnen 0002012383-26-003985 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
EcoR1 Capital, LLC 1.271.342 SH35.368.734 DollarUnverändert Vorquartal: 1.271.342Einreichung öffnen 0000935836-26-000577 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
BAKER BROS. ADVISORS LP 991.691 SH27.588.844 DollarUnverändert Vorquartal: 991.691Einreichung öffnen 0001104659-26-128308 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Trails Edge Capital Partners, LP 964.885 SH26.843.100 DollarHöher um 250.000 Vorquartal: 714.885Einreichung öffnen 0002077247-26-000005 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
T. Rowe Price Investment Management, Inc. 850.123 SH23.651 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001897612-26-000766 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
MPM BIOIMPACT LLC 771.839 SH21.472.561 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001193125-26-463462 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
VANGUARD CAPITAL MANAGEMENT LLC 711.290 SH19.788.088 DollarHöher um 174.765 Vorquartal: 536.525Einreichung öffnen 0002100119-26-001711 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
TORONTO DOMINION BANK 681.337 SH18.954.795 DollarUnverändert Vorquartal: 681.337Einreichung öffnen 0002052595-26-000123 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
FRANKLIN TEMPLETON INC Teilweise unter einem anderen Manager gemeldet630.859 SH17.399.092 DollarHöher um 426.579 Vorquartal: 204.280Einreichung öffnen 0000038777-26-000291 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
STATE STREET CORP Teilweise unter einem anderen Manager gemeldet549.269 SH15.280.664 DollarHöher um 324.947 Vorquartal: 224.322Einreichung öffnen 0000093751-26-000747 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
UBS Group AG Teilweise unter einem anderen Manager gemeldet417.651 SH11.619.051 DollarHöher um 246.362 Vorquartal: 171.289Einreichung öffnen 0001610520-26-000121 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
GEODE CAPITAL MANAGEMENT, LLC Teilweise unter einem anderen Manager gemeldet412.768 SH11.486.618 DollarHöher um 119.586 Vorquartal: 293.182Einreichung öffnen 0001214717-26-000012 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
FMR LLC Teilweise unter einem anderen Manager gemeldet383.249 SH10.661.987 DollarHöher um 87.688 Vorquartal: 295.561Einreichung öffnen 0000315066-26-002964 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
ArrowMark Colorado Holdings LLC 378.829 SH10.539.023 DollarHöher um 36.376 Vorquartal: 342.453Einreichung öffnen 0001172661-26-005265 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Tyro Capital Management LLC 304.401 SH8.468.436 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001915395-26-000018 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Balyasny Asset Management L.P. 303.994 SH8.457.117 DollarNiedriger um 514.712 Vorquartal: 818.706Einreichung öffnen 0001193125-26-463223 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
GREAT POINT PARTNERS LLC Teilweise unter einem anderen Manager gemeldet300.000 SH8.346.000 DollarNiedriger um 52.180 Vorquartal: 352.180Einreichung öffnen 0001172661-26-005345 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Point72 Asset Management, L.P. 238.967 SH6.648.062 DollarHöher um 97.047 Vorquartal: 141.920Einreichung öffnen 0000919574-26-008126 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
MORGAN STANLEY Teilweise unter einem anderen Manager gemeldet221.090 SH6.150.724 DollarHöher um 29.366 Vorquartal: 191.724Einreichung öffnen 0000895421-26-000309 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Driehaus Capital Management LLC 218.528 SH6.079.449 DollarHöher um 75.000 Vorquartal: 143.528Einreichung öffnen 0000938206-26-000066 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Jones Hill Capital LP 217.700 SH6.056.414 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0002102314-26-000006 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Integral Health Asset Management, LLC 200.000 SH5.564.000 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001172661-26-005192 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
MOORE CAPITAL MANAGEMENT, LP 181.479 SH5.048.746 DollarHöher um 39.843 Vorquartal: 141.636Einreichung öffnen 0001448574-26-000004 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
VANGUARD PORTFOLIO MANAGEMENT LLC 174.262 SH4.847.969 DollarHöher um 78.661 Vorquartal: 95.601Einreichung öffnen 0002100121-26-001150 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
MARSHALL WACE, LLP Teilweise unter einem anderen Manager gemeldet168.509 SH4.687.920 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001318757-26-000012 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
Rock Springs Capital Management LP 154.401 SH4.295.436 DollarHöher um 47.651 Vorquartal: 106.750Einreichung öffnen 0001172661-26-005279 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
DAFNA Capital Management LLC 150.532 SH4.187.800 DollarHöher um 61.500 Vorquartal: 89.032Einreichung öffnen 0001389933-26-000010 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
NORTHERN TRUST CORP Teilweise unter einem anderen Manager gemeldet133.034 SH3.701.006 DollarHöher um 29.393 Vorquartal: 103.641Einreichung öffnen 0000073124-26-000067 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
GOLDMAN SACHS GROUP INC Teilweise unter einem anderen Manager gemeldet121.193 SH3.371.589 DollarHöher um 19.917 Vorquartal: 101.276Einreichung öffnen 0000886982-26-000647 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Vestal Point Capital, LP 115.000 SH3.199.300 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001974915-26-000008 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
DEUTSCHE BANK AG\ Teilweise unter einem anderen Manager gemeldet107.949 SH3.003.141 DollarHöher um 1.289 Vorquartal: 106.660Einreichung öffnen 0000948046-26-000083 Eingereicht am 6. Nov. 2026 Diese Zeile anfechten
VANGUARD FIDUCIARY TRUST CO 104.643 SH2.911.168 DollarHöher um 30.381 Vorquartal: 74.262Einreichung öffnen 0000933478-26-000017 Eingereicht am 13. Nov. 2026 Diese Zeile anfechten
CITADEL ADVISORS LLC Teilweise unter einem anderen Manager gemeldet92.858 SH2.583.310 DollarNiedriger um 316.124 Vorquartal: 408.982Einreichung öffnen 0001104659-26-128228 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
DIMENSIONAL FUND ADVISORS LP Teilweise unter einem anderen Manager gemeldet87.700 SH2.440.802 DollarHöher um 55.072 Vorquartal: 32.628Einreichung öffnen 0000354204-26-001096 Eingereicht am 4. Nov. 2026 Diese Zeile anfechten
Woodline Partners LP 83.835 SH2.332.290 DollarUnverändert Vorquartal: 83.835Einreichung öffnen 0001172661-26-005063 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
BLAIR WILLIAM CO/IL 79.081 SH2.200.033 DollarNiedriger um 67.824 Vorquartal: 146.905Einreichung öffnen 0001104659-26-124894 Eingereicht am 10. Nov. 2026 Diese Zeile anfechten
JPMORGAN CHASE CO Teilweise unter einem anderen Manager gemeldet61.953 SH1.758.845 DollarHöher um 71 Vorquartal: 61.882Einreichung öffnen 0000019617-26-000404 Eingereicht am 12. Nov. 2026 Diese Zeile anfechten
Burkehill Global Management, LP 60.000 SH1.669.200 DollarNicht in den gelesenen Einreichungen des Vorquartals Einreichung öffnen 0001013594-26-001202 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
BANK OF AMERICA CORP /DE/ Teilweise unter einem anderen Manager gemeldet51.171 SH1.423.578 DollarHöher um 40.047 Vorquartal: 11.124Einreichung öffnen 0000070858-26-000589 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 49.589 SH1.379.566 DollarHöher um 16.847 Vorquartal: 32.742Einreichung öffnen 0000884546-26-000417 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
ADAR1 Capital Management, LLC 43.800 SH1.218.516 DollarHöher um 36.000 Vorquartal: 7.800Einreichung öffnen 0001940272-26-000033 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Trexquant Investment LP Teilweise unter einem anderen Manager gemeldet43.503 SH1.210.253 DollarNiedriger um 30.259 Vorquartal: 73.762Einreichung öffnen 0001633445-26-000008 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
WELLINGTON MANAGEMENT GROUP LLP Teilweise unter einem anderen Manager gemeldet40.732 SH1.133.164 DollarHöher um 9.339 Vorquartal: 31.393Einreichung öffnen 0000902219-26-000323 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
CITADEL ADVISORS LLC Option: Call Teilweise unter einem anderen Manager gemeldet40.700 SH1.132.274 DollarHöher um 14.000 Vorquartal: 26.700Einreichung öffnen 0001104659-26-128228 Eingereicht am 16. Nov. 2026 Diese Zeile anfechten
Bank of New York Mellon Corp Teilweise unter einem anderen Manager gemeldet38.710 SH1.076.912 DollarHöher um 9.969 Vorquartal: 28.741Einreichung öffnen 0001390777-26-000121 Eingereicht am 5. Nov. 2026 Diese Zeile anfechten
Manager des Vorquartals ohne gelesene Einreichung für das neueste

Sie haben möglicherweise nur noch nicht eingereicht: Das Fehlen in den gelesenen Einreichungen des neuesten Quartals bedeutet nicht, dass die Position verkauft wurde.

  • SCHRODER INVESTMENT MANAGEMENT GROUP 52.300 SH
  • Sixth Street Partners Management Company, L.P. 32.742 SH
  • JANE STREET GROUP, LLC 26.089 SH
  • Mariner, LLC 12.260 SH
  • D. E. Shaw Co., Inc. 9.781 SH
  • Pale Fire Capital SE 9.460 SH
  • Brevan Howard Capital Management LP 8.387 SH
  • Invesco Ltd. 6.658 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 4.200 SH
  • SIMPLEX TRADING, LLC 1.500 SH
  • MERCER GLOBAL ADVISORS INC /ADV 1.432 SH
  • Rockefeller Capital Management L.P. 231 SH
  • Integrated Wealth Concepts LLC 105 SH
  • Truvestments Capital LLC 46 SH
  • Investors Portfolio Services LLC 15 SH
  • NATIONAL BANK OF CANADA /FI/ 8 SH
  • Das Formular 13F umfasst nur Long-Positionen in Wertpapieren nach Section 13(f): keine Short-Positionen und keine Wertpapiere außerhalb dieser Liste.
  • Ein Manager, der für das neueste Quartal noch nicht eingereicht hat, fehlt und steht nicht bei null; die Frist beträgt bis zu 45 Tage nach Quartalsende.
  • Eine Differenz ist der Unterschied zwischen zwei Quartalsstichtagen, keine Transaktion.
  • Eine unter einem anderen Manager gemeldete Position kann auch in dessen Einreichung erscheinen; die Zeilen werden nicht addiert.
  • Positionen, die die Wertpapierliste diesem Unternehmen nicht oder nur mehrdeutig zuordnen kann, werden nicht angezeigt.

5-%-Halter (Schedule 13D und 13G)

Hier werden im strukturierten SEC-Format (ab Ende 2024) eingereichte Schedules gelesen. Frühere sind Freitext und werden nicht gelesen.

5-%-Halter, jüngstes Ereignis zuerst, wie eingereicht
HalterProzent der GattungGehaltene AktienEreignisdatumFormularQuelle
Samsara BioCapital, L.P. Common Stock, $0.000001 par value per share9.01.804.197,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001699737-26-000026 Diese Zeile anfechten
Samsara BioCapital GP, LLC Common Stock, $0.000001 par value per share9.01.804.197,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001699737-26-000026 Diese Zeile anfechten
Samsara Opportunity Fund, L.P. Common Stock, $0.000001 par value per share0.7150.000,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001699737-26-000026 Diese Zeile anfechten
Samsara Opportunity Fund GP, LLC Common Stock, $0.000001 par value per share0.7150.000,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001699737-26-000026 Diese Zeile anfechten
Srinivas Akkaraju Common Stock, $0.000001 par value per share9.71.954.197,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001699737-26-000026 Diese Zeile anfechten
BALYASNY ASSET MANAGEMENT L.P. Common Stock1.52303.994,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001172661-26-005052 Diese Zeile anfechten
BAM GP LLC Common Stock1.52303.994,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001172661-26-005052 Diese Zeile anfechten
Balyasny Asset Management Holdings LP Common Stock1.52303.994,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001172661-26-005052 Diese Zeile anfechten
Dames GP LLC Common Stock1.52303.994,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001172661-26-005052 Diese Zeile anfechten
Dmitry Balyasny Common Stock1.52303.994,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001172661-26-005052 Diese Zeile anfechten
Baker Bros. Advisors LP Common Stock, par value $0.000001 per share4.991.034.522,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001104659-26-128384 Diese Zeile anfechten
Baker Bros. Advisors (GP) LLC Common Stock, par value $0.000001 per share4.991.034.522,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001104659-26-128384 Diese Zeile anfechten
Julian C. Baker Common Stock, par value $0.000001 per share4.991.034.635,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001104659-26-128384 Diese Zeile anfechten
Felix J. Baker Common Stock, par value $0.000001 per share4.991.034.635,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001104659-26-128384 Diese Zeile anfechten
RTW Investments, LP Common Stock, par value $0.000001 per share9.31.897.463,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001493215-26-000196 Diese Zeile anfechten
Roderick Wong Common Stock, par value $0.000001 per share9.31.897.463,0009/30/2026 Eingereicht am 16. Nov. 2026SCHEDULE 13G/AÄnderung 2Einreichung öffnen 0001493215-26-000196 Diese Zeile anfechten
PRUDENTIAL FINANCIAL INC Common11.22.231.357,0009/30/2026 Eingereicht am 7. Okt. 2026SCHEDULE 13GEinreichung öffnen 0001137774-26-000205 Diese Zeile anfechten
Jennison Associates LLC Common Stock11.12.229.08209/30/2026 Eingereicht am 6. Okt. 2026SCHEDULE 13GEinreichung öffnen 0000053417-26-000058 Diese Zeile anfechten
Trails Edge Capital Partners, LP Common Stock, $0.000001 par value per share4.5714.885,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001493152-26-038383 Diese Zeile anfechten
Trails Edge Biotechnology Master Fund, LP Common Stock, $0.000001 par value per share4.5714.885,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001493152-26-038383 Diese Zeile anfechten
Ortav Yehudai Common Stock, $0.000001 par value per share4.5714.885,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001493152-26-038383 Diese Zeile anfechten
Redmile Group, LLC Common Stock, $0.000001 par value9.91.572.202,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 7Einreichung öffnen 0001104659-26-097193 Diese Zeile anfechten
Jeremy C. Green Common Stock, $0.000001 par value9.91.572.202,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 7Einreichung öffnen 0001104659-26-097193 Diese Zeile anfechten
Redmile Biopharma Investments I, L.P. Common Stock, $0.000001 par value5.1812.033,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13G/AÄnderung 7Einreichung öffnen 0001104659-26-097193 Diese Zeile anfechten
BALYASNY ASSET MANAGEMENT L.P. Common Stock5.18818.706,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001172661-26-003430 Diese Zeile anfechten
BAM GP LLC Common Stock5.18818.706,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001172661-26-003430 Diese Zeile anfechten
Balyasny Asset Management Holdings LP Common Stock5.18818.706,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001172661-26-003430 Diese Zeile anfechten
Dames GP LLC Common Stock5.18818.706,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001172661-26-003430 Diese Zeile anfechten
Dmitry Balyasny Common Stock5.18818.706,0006/30/2026 Eingereicht am 14. Aug. 2026SCHEDULE 13GEinreichung öffnen 0001172661-26-003430 Diese Zeile anfechten
Redmile Group, LLC Common Stock, $0.000001 par value9.91.557.179,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 6Einreichung öffnen 0001104659-26-016440 Diese Zeile anfechten
Jeremy C. Green Common Stock, $0.000001 par value9.91.557.179,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 6Einreichung öffnen 0001104659-26-016440 Diese Zeile anfechten
Redmile Biopharma Investments I, L.P. Common Stock, $0.000001 par value4.8749.610,0012/31/2025 Eingereicht am 17. Feb. 2026SCHEDULE 13G/AÄnderung 6Einreichung öffnen 0001104659-26-016440 Diese Zeile anfechten
Trails Edge Capital Partners, LP Common Stock5.1785.000,0012/08/2025 Eingereicht am 15. Dez. 2025SCHEDULE 13GEinreichung öffnen 0001493152-25-027814 Diese Zeile anfechten
Trails Edge Biotechnology Master Fund, LP Common Stock5.1785.000,0012/08/2025 Eingereicht am 15. Dez. 2025SCHEDULE 13GEinreichung öffnen 0001493152-25-027814 Diese Zeile anfechten
Ortav Yehudai Common Stock5.1785.000,0012/08/2025 Eingereicht am 15. Dez. 2025SCHEDULE 13GEinreichung öffnen 0001493152-25-027814 Diese Zeile anfechten
EcoR1 Capital, LLC Common Stock9.91.442.902,0009/30/2025 Eingereicht am 14. Nov. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0000935836-25-000698 Diese Zeile anfechten
Oleg Nodelman Common Stock9.91.442.902,0009/30/2025 Eingereicht am 14. Nov. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0000935836-25-000698 Diese Zeile anfechten
EcoR1 Capital Fund Qualified, L.P. Common Stock8.61.249.344,0009/30/2025 Eingereicht am 14. Nov. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0000935836-25-000698 Diese Zeile anfechten
Commodore Capital LP Common Stock, $0.000001 par value3.0427.866,0006/30/2025 Eingereicht am 14. Aug. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001831942-25-000013 Diese Zeile anfechten
Commodore Capital Master LP Common Stock, $0.000001 par value3.0427.866,0006/30/2025 Eingereicht am 14. Aug. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001831942-25-000013 Diese Zeile anfechten
Baker Bros. Advisors LP Common Stock, par value $0.000001 per share7.0991.691,0006/30/2025 Eingereicht am 14. Aug. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001104659-25-078656 Diese Zeile anfechten
Baker Bros. Advisors (GP) LLC Common Stock, par value $0.000001 per share7.0991.691,0006/30/2025 Eingereicht am 14. Aug. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001104659-25-078656 Diese Zeile anfechten
Julian C. Baker Common Stock, par value $0.000001 per share7.0991.804,0006/30/2025 Eingereicht am 14. Aug. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001104659-25-078656 Diese Zeile anfechten
Felix J. Baker Common Stock, par value $0.000001 per share7.0991.804,0006/30/2025 Eingereicht am 14. Aug. 2025SCHEDULE 13G/AÄnderung 1Einreichung öffnen 0001104659-25-078656 Diese Zeile anfechten

Der Prozentsatz bezieht sich auf die in der Einreichung genannte Gattung, wie vom Halter angegeben. Gruppenmitglieder melden jeweils die Aktien der Gruppe; die Zeilen werden daher nicht addiert.

Was gelesen wurde

2.212.651 Einreichungen gelesen, vom 14. Juni 2004 bis 16. Nov. 2026: Formulare 3, 3/A, 4, 4/A, 5, 5/A.

Jahre können unvollständig sein, solange das Archiv noch gelesen wird. Ein Jahr mit wenigen Einreichungen hier besagt nicht, dass wenige gemacht wurden.

Gelesene Einreichungen nach Einreichungsjahr
EinreichungsjahrGelesene Einreichungen
20151
2016204.322
2017202.494
2018202.048
2019193.638
2020144.184
2021224.474
2022130.393
2023199.811
2024209.823
2025235.520
2026260.165

Einreichungen aus der Zeit vor der XML-Pflicht der SEC sind aufgeführt, aber nicht ausgelesen.

Zurück zu Neurogene Inc.